Plasma leakage in dengue haemorrhagic fever

Thrombosis and Haemostasis

Volumn 102, Issue 6, 2009, Pages 1042-1049

  Srikiatkhachorn, Anon ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Dengue haemorrhagic fever; Dengue viruses; Immune system; Permeability; Plasma leakage

Indexed keywords

BLEEDING; BLOOD TRANSFUSION; CLINICAL FEATURE; DENGUE; DISEASE SEVERITY; ENDEMIC DISEASE; ENDOTHELIUM CELL; HEMORRHAGIC FEVER; HUMAN; IMMUNE SYSTEM; NONHUMAN; PATHOGENESIS; PLAMA LEAKAGE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS REPLICATION;

ANIMALS; CAPILLARY PERMEABILITY; CROSS REACTIONS; DENGUE; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HEMORRHAGE; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, IMMUNOLOGICAL; PLASMA; RISK FACTORS; T-LYMPHOCYTES;

EID: 72949104154     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-03-0208     Document Type: Review

References (92)

1. Organization WH. Dengue and dengue haemorrhagic fever. (http://wwwwhoint/mediacentre/factsheets/ fs117/en/, accessed 1 December 2008).
2. Organization WH, editor. Dengue and dengue haemorrhagic fever. WHO, Geneva; 2000.
3. Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat Q 1997; 50: 161-169.
4. Kouri G, Guzman MG, Valdes L, et al. Reemergence of dengue in Cuba: a 1997 epidemic in Santiago de Cuba. Emerg Infect Dis 1998; 4: 89-92.
5. Gubler D, Kuno G, Markoff L. Flavivirus, Field's Virology. 5th ed. Lippincott Williams & Wilkins; 2007.
6. Lindenbach BD, Thiel H-J, Rice CM. Flaviviridae: The Viruses and Their Replication, Field's Virology. Lippincott Williams & Wilkins; 2007.
7. Jones M, Davidson A, Hibbert L, et al. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 2005; 79: 5414-5420.
8. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005; 79: 8004-8013.
9. Medin CL, Fitzgerald KA, Rothman AL. Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J Virol 2005;79: 11053-11061.
10. Avirutnan P, Punyadee N, Noisakran S, et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. The Journal of infectious diseases 2006; 193: 1078-1088.
11. Organization WH. Dengue Hemorrhagic Fever: diagnosis, treatment, prevention and control. 2nd ed. WHO, WHO; 1997.
12. Pancharoen C, Rungsarannont A, Thisyakorn U. Hepatic dysfunction in dengue patients with various severity. J Med Assoc Thai 2002 ; 85 (Suppl 1): S298-301.
13. Cam BV, Fonsmark L, Hue NB, et al. Prospective case-control study of encephalopathy in children with dengue hemorrhagic fever. Am J Tropical Med Hyg 2001; 65: 848-851.
14. Janssen HL, Bienfait HP, Jansen CL, et al. Fatal cerebral oedema associated with primary dengue infection. J Infect 1998; 36: 344-346.
15. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, et al. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. The Pediatric infectious disease journal 2007; 26: 283-292.
16. Balasubramanian S, Janakiraman L, Kumar SS, et al. A reappraisal of the criteria to diagnose plasma leakage in dengue hemorrhagic fever. Indian Ped 2006; 43: 334-339.
17. Krishnamurti C, Kalayanarooj S, Cutting MA, et al. Mechanisms of hemorrhage in dengue without circulatory collapse. Am J Tropical Med Hyg 2001; 65: 840-847.
18. Nimmannitya S. Clinical manifestations of Dengue/Dengue Haemorrhagic Fever. In: Monograph on Dengue/Dengue Haemorrhagic Fever. World Health Organization, New Delhi; 1993; 48-57.
19. Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. New Engl J Med 2005; 353: 877-889.
20. Burke DS, Nisalak A, Johnson DE, et al. A prospective study of dengue infections in Bangkok. Am J Tropical Med Hyg 1988; 38: 172-180.
21. Endy TP, Chunsuttiwat S, Nisalak A, et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002; 156: 40-51.
22. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977; 265: 739-741.
23. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140: 527-533.
24. Stephens HA, Klaythong R, Sirikong M, et al. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 2002; 60: 309-318.
25. Soundravally R, Hoti SL. Polymorphisms of the TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection. Scand J Immunol 2008; 67: 618-625.
26. Sakuntabhai A, Turbpaiboon C, Casademont I, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005; 37: 507-513.
27. Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, et al. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 2004; 64: 469-472.
28. Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997; 230: 244-251.
29. Kochel TJ, Watts DM, Halstead SB, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002; 360: 310-312.
30. Rodrigo WW, Alcena DC, Kou Z, et al. Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin Vaccine Immunol 2009; 16: 285-287.
31. Holden KL, Harris E. Enhancement of dengue virus translation: role of the 3′ untranslated region and the terminal 3′ stem-loop domain. Virology 2004; 329: 119-133.
32. Leitmeyer KC, Vaughn DW, Watts DM, et al. Dengue virus structural differences that correlate with pathogenesis. J Virology 1999; 73: 4738-4747.
33. Barth OM, Barreto DF, Paes MV, et al. Morphological studies in a model for dengue-2 virus infection in mice. Mem Inst Oswaldo Cruz 2006; 101: 905-915.
34. Kyle JL, Beatty PR, Harris E. Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis 2007; 195: 1808-1817.
35. Shresta S, Sharar KL, Prigozhin DM, et al. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virology 2006; 80: 10208-10217.
36. Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virology 2009; 83: 8638-8645.
37. Bente DA, Melkus MW, Garcia JV, et al. Dengue fever in humanized NOD/SCID mice. J Virology 2005; 79: 13797-13799.
38. Bhamarapravati N, Tuchinda P, Boonyapaknavik V. Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. Ann Trop Med Parasitol 1967; 61: 500-510.
39. Jessie K, Fong MY, Devi S, et al. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 2004; 189: 1411-1418.
40. Balsitis SJ, Coloma J, Castro G, et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. The American journal of tropical medicine and hygiene 2009; 80: 416-424.
41. Limonta D, Capo V, Torres G, et al. Apoptosis in tissues from fatal dengue shock syndrome. J Clin Virol 2007; 40: 50-54.
42. Marovich M, Grouard-Vogel G, Louder M, et al. Human dendritic cells as targets of dengue virus infection. J Investig Dermatol Symp Proc 2001; 6: 219-224.
43. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003; 197: 823-829.
44. Pokidysheva E, Zhang Y, Battisti AJ, et al. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 2006; 124: 485-493.
45. Libraty DH, Pichyangkul S, Ajariyakhajorn C, et al. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. Journal of virology 2001; 75: 3501-358.
46. Ho LJ, Wang JJ, Shaio MF, et al. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol 2001; 166: 1499-1506.
47. Taweechaisupapong S, Sriurairatana S, Angsubhakorn S, et al. In vivo and in vitro studies on the morphological change in the monkey epidermal Langerhans cells following exposure to dengue 2 (16681) virus. Southeast Asian J Trop Med Public Health 1996; 27: 664-672.
48. Wu SJ, Grouard-Vogel G, Sun W, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6: 816-820.
49. Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185: 1213-1221.
50. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181: 2-9.
51. Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002; 186: 1165-1168.
52. Bosch I, Xhaja K, Estevez L, et al. Increased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challenge. J Virology 2002; 76: 5588-5597.
53. Carr JM, Hocking H, Bunting K, et al. Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers. J Med Virol 2003; 69: 521-528.
54. Lee YR, Liu MT, Lei HY, et al. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/ dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol 2006; 87: 3623-3630.
55. Cardier JE, Marino E, Romano E, et al. Proinflammatory factors present in sera from patients with acute dengue infection induce activation and apoptosis of human microvascular endothelial cells: possible role of TNF-alpha in endothelial cell damage in dengue. Cytokine 2005; 30: 359-365.
56. Avirutnan P, Malasit P, Seliger B, et al. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 1998; 161: 6338-6346.
57. Green S, Pichyangkul S, Vaughn DW, et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis 1999; 180: 1429-1435.
58. Mathew A, Kurane I, Green S, et al. Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J Virology 1998; 72: 3999-4004.
59. Mongkolsapaya J, Dejnirattisai W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9: 921-927.
60. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol 2006; 176: 3821-3829.
61. Dong T, Moran E, Vinh Chau N, et al. High Pro-Inflammatory Cytokine Secretion and Loss of High Avidity Cross-Reactive Cytotoxic T-Cells during the Course of Secondary Dengue Virus Infection. PloS one 2007; 2: e1192.
62. Beaumier CM, Mathew A, Bashyam HS, et al. Cross-reactive memory CD8(+) T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. J Infect Dis 2008; 197: 608-617.
63. Bashyam HS, Green S, Rothman AL. Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol 2006; 176: 2817-2824.
64. Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 2005; 175: 2676-2683.
65. Lin CF, Lei HY, Shiau AL, et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol 2003; 69: 82-90.
66. Lin CF, Lei HY, Shiau AL, et al. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol 2002; 169: 657-664.
67. Lin CF, Wan SW, Chen MC, et al. Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Lab Invest 2008; 88: 1079-1089.
68. Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997; 142: 897-916.
69. Sun DS, King CC, Huang HS, et al. Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. J Thromb Haemost 2007; 5: 2291-2299.
70. Yen YT, Chen HC, Lin YD, et al. Enhancement by tumor necrosis factor alpha of dengue virus-induced endothelial cell production of reactive nitrogen and oxygen species is key to hemorrhage development. J Virology 2008; 82: 12312-12324.
71. Chen HC, Hofman FM, Kung JT, et al. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virology 2007; 81: 5518-5526.
72. Warke RV, Xhaja K, Martin KJ, et al. Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J Virology 2003; 77: 11822-11832.
73. Huang YH, Lei HY, Liu HS, et al. Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production. Am J Tropical Med Hyg 2000; 63: 71-75.
74. Jiang Z, Tang X, Xiao R, et al. Dengue virus regulates the expression of hemostasis-related molecules in human vein endothelial cells. J Infect 2007; 55: e23-28.
75. Huang YH, Lei HY, Liu HS, et al. Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. J Med Virol 2003; 70: 610-616.
76. Huerta-Zepeda A, Cabello-Gutierrez C, Cime-Castillo J, et al. Crosstalk between coagulation and inflammation during Dengue virus infection. Thromb Haemost 2008; 99: 936-943.
77. Cabello-Gutierrez C, Manjarrez-Zavala ME, Huerta-Zepeda A, et al. Modification of the cytoprotective protein C pathway during Dengue virus infection of human endothelial vascular cells. Thromb Haemost 2009; 101: 916-928.
78. Butthep P, Chunhakan S, Tangnararatchakit K, et al. Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. Ped Infect Dis J 2006; 25: 894-897.
79. Anderson R, Wang S, Osiowy C, et al. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virology 1997; 71: 4226-4232.
80. Peyrefitte CN, Pastorino B, Grau GE, et al. Dengue virus infection of human microvascular endothelial cells from different vascular beds promotes both common and specific functional changes. J Med Virol 2006; 78: 229-242.
81. Zhang JL, Wang JL, Gao N, et al. Up-regulated expression of beta3 integrin induced by dengue virus serotype 2 infection associated with virus entry into human dermal microvascular endothelial cells. Biochem Biophys Res Commun 2007; 356: 763-768.
82. Srikiatkhachorn A, Ajariyakhajorn C, Endy TP, et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever. J Virology 2007; 81: 1592-1600.
83. Luplertlop N, Misse D, Bray D, et al. Dengue-virusinfected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep 2006; 7: 1176-1181.
84. Luplertlop N, Misse D. MMP cellular responses to dengue virus infection-induced vascular leakage. Jpn J Infect Dis 2008; 61: 298-301.
85. Dewi BE, Takasaki T, Kurane I. Peripheral blood mononuclear cells increase the permeability of dengue virus-infected endothelial cells in association with downregulation of vascular endothelial cadherin. J Gen Virol 2008; 89: 642-652.
86. Schnittler HJ, Feldmann H. Viral hemorrhagic fever-a vascular disease? Thromb Haemost 2003; 89: 967-972.
87. Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nature Immunol 2007; 8: 1159-1164.
88. Zaki SR, Greer PW, Coffield LM, et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 1995; 146: 552-579.
89. Agarwal R, Elbishbishi EA, Chaturvedi UC, et al. Profile of transforming growth factor-beta 1 in patients with dengue haemorrhagic fever. Int J Exp Pathol 1999; 80: 143-149.
90. Laur F, Murgue B, Deparis X, et al. Plasma levels of tumour necrosis factor alpha and transforming growth factor beta-1 in children with dengue 2 virus infection in French Polynesia. Transact Royal Soc Trop Med Hyg 1998; 92: 654-656.
91. Sironen T, Klingstrom J, Vaheri A, et al. Pathology of Puumala hantavirus infection in macaques. PloS one 2008; 3: e3035.
92. Kilpatrick ED, Terajima M, Koster FT, et al. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J Immunol 2004; 172: 3297-3304.